<DOC>
	<DOCNO>NCT01581788</DOCNO>
	<brief_summary>The purpose study assess bioequivalence Divalproex Sodium ER Tablets 500 mg Dr. Reddy 's Depakote ER 500 mg Tablets Abbott Laboratories healthy , adult , human subject , feed condition monitor adverse event ensure safety subject .</brief_summary>
	<brief_title>Bioequivalence Study Divalproex Sodium ER Tablets , 500 mg Under Fed Conditions</brief_title>
	<detailed_description>Open label , balance , randomize , two-treatment , two-sequence , two-period , single-dose , crossover oral bioequivalence study Divalproex Sodium Extended Release Tablets 500 mg Dr. Reddy 's Laboratories Limited , Depakote ER 500 mg mg Tablets Abbott Laboratories healthy , adult , human subject , fed condition .</detailed_description>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>The subject select study participation , meet follow criterion : 1 . Subjects age 18 45 year ( inclusive ) . 2 . Subjects ' weight within normal range accord normal value Body Mass Index ( 18.5 24.9 kg/m2 ) minimum 50 kg weight . 3 . Subjects normal health determine personal medical history , clinical examination laboratory examination within clinically acceptable reference range . 4 . Subjects normal 12lead electrocardiogram ( ECG ) . 5 . Subjects normal chest XRay ( P/A view ) whose XRay take 6 month prior dose Period 01 . 6 . Subjects negative urine screen drug abuse ( include amphetamine , barbiturate , benzodiazepine , marijuana , cocaine , morphine ) . 7 . Subjects negative alcohol breath test . 8 . Subjects willing adhere protocol requirement provide write informed consent . The subject exclude study , meet follow criterion : 1 . Hypersensitivity Divalproex related class drug . 2 . History presence significant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , endocrine , immunological , dermatological , neurological psychiatric disease disorder . 3 . Any treatment could bring induction inhibition hepatic microsomal enzyme system within 1 month study start . 4 . History presence significant alcoholism drug abuse . 5 . History presence significant smoking ( 10 cigarette beedi's/day ) . 6 . History presence asthma , urticaria significant allergic reaction . 7 . History presence significant gastric and/or duodenal ulceration . 8 . History presence significant thyroid disease , adrenal dysfunction , organic intracranial lesion pituitary tumor . 9 . History presence cancer . 10 . Difficulty donate blood . 11 . Difficulty swallow solid like tablet capsule . 12 . Use prescribed OTC medication last two week prior dose period 01 . 13 . Major illness 3 month screen . 14 . Participation drug research study within past 3 month . 15 . Donation blood past 3 month screen . 16 . Consumption grapefruit juice , xanthinecontaining product , tobacco containing product alcohol within 48 hour prior dose . 17 . Positive screen test one : HIV , Hepatitis B Hepatitis C. 18 . History presence significant easy bruise bleeding . 19 . History presence significant recent trauma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Divalproex Sodium</keyword>
	<keyword>Crossover</keyword>
</DOC>